Tc99m Sestamibi Molecular Breast Imaging

NAActive, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 15, 2015

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Breast Cancer
Interventions
PROCEDURE

Molecular Breast Imaging (MBI)

Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.

DRUG

Tc99m sestamibi

8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02324387 - Tc99m Sestamibi Molecular Breast Imaging | Biotech Hunter | Biotech Hunter